RT Journal Article
SR Electronic
T1 Prevalence of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20097808
DO 10.1101/2020.05.11.20097808
A1 Pablos, José L.
A1 Abasolo-Alcázar, Lydia
A1 Álvaro-Gracia, José M.
A1 Blanco, Francisco J.
A1 Blanco, Ricardo
A1 Castrejón, Isabel
A1 Fernández-Fernández, David
A1 Fernández-Gutierrez, Benjamín
A1 Galindo, María
A1 González-Gay, Miguel A.
A1 Manrique-Arija, Sara
A1 Mena-Vázquez, Natalia
A1 Mera-Varela, Antonio
A1 Retuerto, Miriam
A1 Seijas-Lopez, Álvaro
A1 RIER investigators group
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.05.11.20097808.abstract
AB Background The susceptibility of patients with rheumatic diseases, and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.Methods We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with SARS-CoV-2 positive PCR tests performed in the hospital to the same reference populations. Incidences of PCR+ confirmed COVID-19 were compared among groups.Results Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Systemic autoimmune or immune mediated diseases (AI/IMID) patients showed a significant increase, whereas inflammatory arthritis (IA) or systemic lupus erythematosus (SLE) patients did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. IA patients on targeted-synthetic or biological disease-modifying antirheumatic drugs (ts/bDMARD), but not those on conventional-synthetic (csDMARD), had a greater prevalence despite a similar age distribution.Conclusion Patients with AI/IMID show a variable risk of hospital diagnosed COVID-19. Interplay of aging, therapies, and disease specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyze the specific factors involved in COVID-19 susceptibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was performed by the RIER research network which was supported by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (RD16/0012 RETICS program), and cofinanced by the European Regional Development Fund (FEDER).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost data are included in the manuscript. Additional data can be shared upon reasoned request to the corresponding author.